INTEGRATED SAFETY OF LESINURAD, A NOVEL URIC ACID REABSORPTION INHIBITOR FOR THE TREATMENT OF GOUT

被引：0

作者：

Becker, M. A. ^{[1
]}

Keenan, R. T. ^{[2
]}

Khanna, P. P. ^{[3
]}

Malamet, R. ^{[4
]}

Bos, K. ^{[4
]}

Li, J. ^{[4
]}

Hu, J. ^{[5
]}

White, W. B. ^{[6
]}

机构：

[1] Univ Chicago, Chicago, IL 60637 USA

[2] Duke Univ, Sch Med, Durham, NC USA

[3] Univ Michigan, Ann Arbor, MI 48109 USA

[4] AstraZeneca, Wilmington, DE USA

[5] Formerly Ardea Biosci Inc, San Diego, CA USA

[6] Univ Connecticut, Sch Med, Farmington, CT USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷

关键词：

D O I：

10.1136/annrheumdis-2017-eular.3674

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

THU0444

引用

页码：375 / 376

页数：2

共 50 条

[21] Physiological modeling of uric acid in man: application to assess benefit-risk of lesinurad in gout
Aksenov, Sergey
Eriksson, Ulf
Stanski, Donald
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S34 - S35
[22] Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
Jeffrey N. Miner
Philip K. Tan
David Hyndman
Sha Liu
Cory Iverson
Payal Nanavati
David T. Hagerty
Kimberly Manhard
Zancong Shen
Jean-Luc Girardet
Li-Tain Yeh
Robert Terkeltaub
Barry Quart
Arthritis Research & Therapy, 18
[23] LESINURAD, A SELECTIVE URIC ACID REABSORPTION INHIBITOR, IN COMBINATION WITH XANTHANE OXIDASE INHIBITORS: SUA AND FLARES COMPOSITE ENDPOINT FROM PHASE III STUDIES IN GOUT PATIENTS (CLEAR 1, CLEAR 2 AND CRYSTAL)
Khanna, P. P.
Baumgartner, S.
Robinson, J.
Tafesse, E.
Morlock, R.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 382 - 383
[24] Metabolism and Disposition of Verinurad, a Uric Acid Reabsorption Inhibitor, in Humans
Lee, Caroline A.
Yang, Chun
Shah, Vishal
Shen, Zancong
Wilson, David M.
Ostertag, Traci M.
Girardet, Jean-Luc
Hall, Jesse
Gillen, Michael
DRUG METABOLISM AND DISPOSITION, 2018, 46 (05) : 532 - 541
[25] TREATMENT OF GOUT BY REDUCTION OF URIC ACID PRRODUCTION
KERSLEY, GD
ANNALS OF THE RHEUMATIC DISEASES, 1966, 25 (04) : 353 - +
[26] TREATMENT OF GOUT AND CONSERVATIVE TREATMENT OF URIC-ACID NEPHROLITHIASIS
ZOLLNER, N
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1968, 93 (07) : 310 - &
[27] TREATMENT OF GOUT AND DISORDERS OF URIC ACID METABOLISM WITH ALLOPURINOL
OGRYZLO, MA
UROWITZ, MB
WEBER, HM
HOUPT, JB
CANADIAN MEDICAL ASSOCIATION JOURNAL, 1966, 95 (22) : 1120 - +
[28] TREATMENT OF GOUT AND DISORDERS OF URIC ACID METABOLISM WITH ALLOPURINOL
UROWITZ, MB
OGRYZLO, MA
HOUPT, JB
WEBER, HM
ARTHRITIS AND RHEUMATISM, 1966, 9 (03): : 548 - &
[29] ALLOPURINOL IN TREATMENT OF GOUT AND URIC-ACID NEPHROLITHIASIS
ZOLLNER, N
SCHATTENKIRCHNER, M
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1967, 92 (14) : 654 - +
[30] LESINURAD, AN INHIBITOR OF THE URIC ACID TRANSPORTER URAT1 AND A POTENTIAL THERAPY FOR GOUT, REQUIRES URAT1 PHENYLALANINE 365 FOR HIGH AFFINITY INHIBITION
Tan, P. K.
Hyndman, D.
Miner, J. N.
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 780 - 780

← 1 2 3 4 5 →